GenBio AI

Biotech · AI · Computational Biology

Launch

GenBio AI unveils AIDO Cell, first world model simulating a human cell

Drug development burns over a decade and $2 billion per approved compound, and this system aims to simulate that failure before it reaches the lab.

• GenBio AI, co-founded by Nobel laureate David Baker, unveiled AIDO Cell on Aug. 18, 2026 — a virtual cell world model that simulates human cellular behavior from DNA and RNA through proteins to whole-cell responses.
• GenBio AI is an 'AI for Science' startup founded in 2024, led by Baker and AI scientist Eric Xing, headquartered in Palo Alto with labs in Paris and Abu Dhabi.
• The model is both multiscale and stateful, meaning it remembers prior perturbations so researchers can chain interventions and watch cumulative effects, rather than resetting each experiment.
• As an initial proof-of-concept, AIDO Cell reproduced the known mechanism of the drug imatinib in K562 leukemia cells, though GenBio has not disclosed quantitative accuracy metrics or comparisons to rival models.
• GenBio frames the problem starkly: only about 1 in 10,000 drug compounds reaches the clinic, a process that takes over a decade and roughly $2 billion per approved drug.
• AIDO Cell builds on GenBio's earlier AIDO.Cell-100M, a 100-million-parameter transcriptomic model trained on roughly 50 million cells and hosted on the Chan Zuckerberg Initiative's Virtual Cells Platform.
• GenBio plans to launch an early access program giving academic and industry researchers hands-on use of AIDO Cell, currently limited to K562 and HepG2 cell lines.
• Where AlphaFold cracked individual protein structures, a working full-hierarchy cell simulator would let researchers test drug and gene interventions computationally before costly wet-lab experiments, reshaping early-stage discovery economics.